162 related articles for article (PubMed ID: 37517099)
1. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients.
Xu X; Wang Y; Hu X; Zhu Y; Wang J; Guo J
Neoplasia; 2023 Sep; 43():100919. PubMed ID: 37517099
[TBL] [Abstract][Full Text] [Related]
2. Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression.
Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
Cancer Res Treat; 2023 Oct; 55(4):1321-1336. PubMed ID: 37024096
[TBL] [Abstract][Full Text] [Related]
3. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression.
Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
Immunogenetics; 2023 Apr; 75(2):133-143. PubMed ID: 36515717
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract][Full Text] [Related]
5. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
[TBL] [Abstract][Full Text] [Related]
6. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract][Full Text] [Related]
7. Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Urol Oncol; 2023 Jan; 41(1):51.e13-51.e23. PubMed ID: 36328922
[TBL] [Abstract][Full Text] [Related]
8. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
[TBL] [Abstract][Full Text] [Related]
9. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
Fitzgerald KN; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Aggen DH; Carlo MI; Shah NJ; Voss MH; Feldman DR; Motzer RJ; Lee CH
Eur Urol; 2023 Mar; 83(3):195-199. PubMed ID: 36344318
[TBL] [Abstract][Full Text] [Related]
10. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
11. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.
Bolek H; Yekedüz E; Ürün Y
Cancer Treat Rev; 2024 Jan; 122():102667. PubMed ID: 38101099
[TBL] [Abstract][Full Text] [Related]
12. HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
Cancer Immunol Immunother; 2018 Jan; 67(1):79-87. PubMed ID: 28918459
[TBL] [Abstract][Full Text] [Related]
13. PYCR in Kidney Renal Papillary Cell Carcinoma: Expression, Prognosis, Gene Regulation Network, and Regulation Targets.
Shao Z; Lu L; Cui Y; Deng L; Xu Q; Liang Q; Lu X; Zhang J; Chen J; Situ Y
Front Biosci (Landmark Ed); 2022 Dec; 27(12):336. PubMed ID: 36624948
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
[TBL] [Abstract][Full Text] [Related]
15. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C
Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357
[TBL] [Abstract][Full Text] [Related]
16.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
19. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
20. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
Lee D; Gittleman H; Weinstock C; Suzman D; Bloomquist E; Agrawal S; Brave M; Brewer J; Fallah J; Singh H; Tang S; Ibrahim A; Pazdur R; Beaver JA; Amiri-Kordestani L
Eur Urol; 2023 Oct; 84(4):373-378. PubMed ID: 37271635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
